For Shire, Life After Adderall XR? Yes
Executive Summary
Shire has scaled its Adderall XR patent cliff, replenishing lost blockbuster sales with revenues from niche products, smart life-cycle management, and some good-old-fashioned luck. IN VIVO interviews CEO Angus Russell.
You may also be interested in...
Shire CEO Angus Russell On The Value Proposition For Drugs
Since 2008, Shire PLC 's market cap has nearly doubled ($8.3 billion to $16 billion) and its employee count has grown from 1,600 to roughly 4,300. Analysts say the U.K. company is on track to deliver its revenue guidance of 15% compound annual growth rate (CAGR) through 2015 – far above the expected anemic performance of most pharmaceutical companies.
Sanofi And Genzyme: Do Big Pharmas And Orphan Drugs Fit Together?
Big pharmas from Pfizer to GlaxoSmithKline are expanding their initiatives in niche disease areas, but if Sanofi-Aventis acquires Genzyme as it hopes, the French drug maker could soon emerge as an orphan drug leader
Sanofi And Genzyme: Do Big Pharmas And Orphan Drugs Fit Together?
If successful, Sanofi-Aventis' attempt to acquire Genzyme would catapult the company into the orphan drug business, marking Big Pharma's most aggressive strategy in the space to date.